We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reveals First Generic Challenge to Celgene’s Cancer Drug Revlimid
FDA Reveals First Generic Challenge to Celgene’s Cancer Drug Revlimid
August 31, 2010
The FDA has received an ANDA to market a generic version of Revlimid 25 mg, the first challenge to Celgene’s blockbuster cancer drug.